Appendix A: pCODR Clinician Conflict of Interest Declarations

Please Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician:					Dr. Sandeep Sehdev			
Name of drug and indication under review:					·			
Ν	ame (of drug and indica	atior	n under review:	Perjeta for early stage breast cancer			
Co	onfli	ct of Interest	: De	eclarations				
re\ po inf	view p tentia orma	process must disclost al conflicts of inte tion submitted. Co	ose a rest onfli	any conflicts of inte that may influence	e pCODR process, all participants in the pCODR erest. A registered clinician must declare any e or have the appearance of influencing the aration is requested for transparency — it does not.			
Exa	ample	es of conflicts of in	ntere	est include, but are	e not limited to:			
	l • ;	research grants, h	onor	aria, gifts, and sal	al industry or other entities e.g., educational or ary; ationships with drug manufacturers or other interest			
Se	ction	A: Payment Rece	ivec	1				
1.		evious two years from any company or tinterest in the drug under review?						
	x	Yes No						
	lf n	o, please go to Se	ctio	n B				
2.	Wha	t form of paymen	t did	you receive? (Che	eck all that apply.)			
		Advisory board		Program or Opera (e.g., website)	iting Funding			
	X	Conference attendance		Research/educat	ional grants			
		Royalties		Travel grants				
		Gifts		Sponsorship of Ev				
		Honoraria		Other, please spe	CIIY;			

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Hoffman La-Roche Canada,				
Section B: Holdings or Other Interests				
Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.				
No				
Section C: Affiliations, personal or commercial relationships				
Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.				
No				

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: Mar 11/18 Name: Dr. Sandeep Sehdev Signature:



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth-ca/pcodr/registration</u> for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Andrea Eisen

Name of drug and indication under review: pertuzumab—trastuzumab/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- · affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes (UNO If no, please go to Section B. 2. What form of payment did you receive? (Check all that apply.) Advisory role (e.g., advisory boards, Program or Operating Funding HTA submission advice) (e.g., website) Conference attendance Research/educational grants Royalties Travel grants Gifts Sponsorship of Events Honoraria Other, please specify: Click here to enter text.

3. Please provide the names of companies and organizations and the amounts of the payments in the box below.

Click here to enter text



Before completing this template, be sure to <u>register</u> with the pCODR program.

Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

Click here to enter text.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date:

Click here to enter text. An IUIF

Name:

Click here to enter text. A Gusu (Andrea Eisen)

Signature:

Click here to enter text.

Our cancer centre has partupoled in

chuicel trials of Pulso welet and

perturumals. I have not permally

re cerve d

my conpensati

related to

these trals

Alun



Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Annie Ngan

Name of drug and indication under review: pertuzumab-trastuzumab/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes ☐ No If no, please go to Section B.										
		Advisory role (e.g., advisory boards, HTA submission advice)		Program or Operating Funding (e.g., website)						
		Conference attendance		Research/educational grants						
		Royalties		Travel grants						
		Gifts		Sponsorship of Events						
		Honoraria								
	☐ Other, please specify: Click here to enter text.									
3.		e provide the names of companies and box below.	organ	izations and the amounts of the payments						
Cli	ck here	to enter text.								



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit <u>https://www.cadth.ca/pcodr/registration</u> for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

Click here to enter text.

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: April 6th, 2018

Name: Annie Ngan

Signature:



Before completing this template, be sure to register with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

pCODR Clinician Conflict of Interest Declarations

Note: Each registered clinician must complete their own separate pCODR Clinician Conflict of Interest Declarations Template even if the submission is made jointly.

Name of registered clinician: Dr. Orit Freedman

Name of drug and indication under review: pertuzumab-trastuzumab/BC

Conflict of Interest Declarations

To maintain the objectivity and credibility of the pCODR process, all participants in the pCODR review process must disclose any conflicts of interest. A registered clinician must declare any potential conflicts of interest that may influence or have the appearance of influencing the information submitted. Conflict of interest declaration is requested for transparency — it does not negate or preclude the use of the clinician input.

Examples of conflicts of interest include, but are not limited to:

- financial support from the pharmaceutical industry or other entities e.g., educational or research grants, honoraria, gifts, and salary;
- affiliations or personal or commercial relationships with drug manufacturers or other interest groups.

Section A: Payment Received 1. Have you received any payments over the previous two years from any company or organization that may have direct or indirect interest in the drug under review? ☐ Yes ☑ No										
If no, please go to Section B.										
2. What form of payment did you receive? (Check all that apply.)										
		Advisory role (e.g., advisory boards, HTA submission advice) Conference attendance		Program or Operating Funding (e.g., website) Research/educational grants						
		Royalties		Travel grants						
		Gifts		Sponsorship of Events						
		Honoraria								
	☐ Other, please specify: Click here to enter text.									
3.	Please provide the names of companies and organizations and the amounts of the payments in the box below.									
Cli	ck here	to enter text.								



Before completing this template, be sure to <u>register</u> with the pCODR program. Please visit https://www.cadth.ca/pcodr/registration for information about the registration process.

Section B: Holdings or Other Interests

Have you received or is it in possession of stocks or options of more than \$10,000 (excluding mutual funds) for organizations that may have a direct or indirect interest in the drug under review? If yes, please list in the table below.

no

Section C: Affiliations, personal or commercial relationships

Do you have personal or commercial relationships either with a drug or health technology manufacturer (including such manufacturer's parent corporation, subsidiaries, affiliates and associated corporations) or other interest groups? If yes, please provide the names of the companies and organizations and outline the nature of these relationships in the table below.

I have participated in a clinical trial with this medication

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential or perceived conflict of interest situation.

Date: 12/04/18

Name: Orit Freedman

Signature: OF